Trial Profile
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects With Seizure Clusters
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Midazolam (Primary)
- Indications Generalised epilepsy; Partial epilepsies; Seizures
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIS1
- Sponsors Proximagen; UCB Biopharma; Upsher-Smith
- 01 May 2020 Results of post-hoc analysis of ARTEMIS-1 and ARTEMIS-2 presented at the 72nd Annual Meeting of the American Academy of Neurology
- 10 Dec 2019 Results of post hoc analysis characterizing somnolence and its potential effect on patients returning to full baseline functionality after MDZ-NS administration presented at the 73rd Annual Meeting of the American Epilepsy Society
- 29 May 2019 Results assessing safety and efficacy of midazolam in patients with seizure published in the Epilepsia